Many patients with Prader-Willi syndrome may manifest psychotic symptoms that meet the diagnostic criteria of cycloid psychosis, a study shows. However, this particular psychological condition is often disregarded by clinicians, which may prevent prompt and adequate care. This finding was reported in a study, “…
News
Europe’s umbrella organization for 800 rare disease associations has developed a sweeping initiative to help the continent’s 30 million rare disease patients and their caregivers learn about their conditions, find assistance and receive treatment. Eurordis-Rare Diseases Europe hopes to improve the current piecemeal treatment and support program with a holistic,…
A new case report illustrates the importance of prenatal genetic tests when clinical signs strongly suggest a diagnosis of Prader-Willi syndrome (PWS). The study, “Possibility of early diagnosis in a fetus affected by Prader-Willi syndrome with maternal hetero-UPD15: A lesson to be learned,” was published in the…
People with rare diseases know that the right government policies can make a big difference in the quality of their own lives, and those of their caregivers. But most lawmakers aren’t experts in even one well-known disease — let alone the world’s estimated 7,000 rare disorders. So how does the…
Long-term exercise improves physical performance in patients with Prader-Willi syndrome (PWS), but immediate physiological response post-exercise appears unfavorable, a review of published studies shows. The study, “Physical exercise and Prader-Willi syndrome: A systematic review.” was published in the journal Clinical Endocrinology. PWS is associated with abnormal body composition and…
A group of clinicians has established a series of guidelines for the treatment of people with Prader-Willi syndrome (PWS). The guidelines are already being implemented at Tennessee’s Prader-Willi Clinic at Monroe Carell Jr. Children’s Hospital at Vanderbilt. The new guidelines were described in the study, “A multidisciplinary approach…
The Foundation for Prader-Willi Research (FPWR) recently announced the first-round winners of its 2019 research awards, which collectively totals a financial investment of $786,000 in grants. Theresa Strong, PhD, the foundation’s director of research programs, described the projects of the eight grant recipients and how their investigations may…
A research project aiming to uncover whether awakening “sleeping” genes could overcome the genetic errors underlying Prader-Willi syndrome (PWS) and lessen disease severity, has earned funding from the Prader-Willi Research Foundation of Australia and the U.S. Foundation for Prader-Willi Research. “[W]e hope they might help people with Prader-Willi syndrome by…
Biotech company Saniona announced the formation of a scientific advisory board to supervise and guide the developmental program of Tesomet (tesofensine/metoprolol) for patients with Prader-Willi Syndrome (PWS). The company also extended its Phase 2a open-label study (NCT03149445), testing the safety and efficacy of the treatment, in the…
Millendo Therapeutics presented an overview of its Phase 2b/3 clinical trial testing the long-term safety and efficacy of livoletide — a potential first-in-class treatment to control hyperphagia (excessive hunger) and food-related behaviors in Prader-Willi syndrome (PWS) — at the 21st European Congress of Endocrinology on May 18–21, 2019,…
Recent Posts
- Heart activity changes prompted pause in trial of ARD-101 in PWS
- ‘Telemental health’ may help ease stress for caregivers of PWS children
- Severe sleep apnea in PWS children strongly linked to extra weight: Study
- Advocating for your child with Prader-Willi syndrome is a lifelong endeavor
- Collecting pop tabs is a small act that makes a big impact
- Safety concerns over PWS therapy ARD-101 pause global clinical trial
- Starting growth hormone before age 2 does not harm PWS sleep
- I’m hopeful a new treatment will benefit my son with Prader-Willi syndrome
- Palatin to test 2 obesity-targeting drugs for PWS in clinical trials this year
- Still-recruiting ARD-101 trial for PWS lowers US enrollment age to 7